Privi Speciality Chemicals Limited has informed the Exchange regarding 'BM Outcome - Unaudited Financial Results'.
PRIVISCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 1.7 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Privi Speciality Chemicals reported strong Q1 FY26 results with standalone revenue from operations rising to Rs. 56,635.59 lakhs, up about 28% from Rs. 44,116.43 lakhs in the same quarter last year. Standalone net profit more than doubled to Rs. 6,563.27 lakhs (from Rs. 3,221.46 lakhs), with EPS at Rs. 17.58 vs Rs. 8.25 a year ago. On a consolidated basis, revenue grew roughly 20% to Rs. 55,881.24 lakhs and net profit jumped to Rs. 5,755.22 lakhs from Rs. 3,145.35 lakhs. However, the three subsidiaries (including Privi Biotechnologies, USA Corp, and Prigiv Specialties) together reported a net loss of Rs. 1,014.28 lakhs before consolidation. Statutory auditors BSR & Co. LLP issued an unmodified (clean) limited review conclusion on both standalone and consolidated results.
Sharp improvement in both top line and bottom line on a YoY basis, with profits roughly doubling standalone, signals strong operating performance in the Aroma Chemicals segment and is likely to be viewed positively by investors. The subsidiary-level losses are a minor concern but did not drag the overall group into the red.